Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II

Diabetes, Obesity and Metabolism

Volumn 19, Issue 7, 2017, Pages 989-996

  Leiter, Lawrence A ^a   Zamorano, José Luis ^b   Bujas Bobanovic, Maja ^c   Louie, Michael J ^d   Lecorps, Guillaume ^c   Cannon, Christopher P ^e   Handelsman, Yehuda ^f  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c SANOFI   (France)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Metabolic Institute of America   (United States)

Author keywords

cardiovascular disease; clinical trial; dyslipidaemia; type 1 diabetes; type 2 diabetes

Indexed keywords

ALIROCUMAB; ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISORDERS OF HIGHER CEREBRAL FUNCTION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; RANDOMIZED CONTROLLED TRIAL; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DIABETIC COMPLICATION; DRUG ADMINISTRATION; FOLLOW UP; HEALTHY LIFESTYLE; HYPERLIPIDEMIA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; COMBINED MODALITY THERAPY; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEALTHY LIFESTYLE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASE 9; RISK FACTORS; SERINE PROTEINASE INHIBITORS;

EID: 85018616526     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12909     Document Type: Article

References (13)

1. Verges B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58:886-899.
2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl):S1-S45.
3. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818.
4. American Diabetes Association. 8. Cardiovascular disease and risk management. Diabetes Care. 2015;38(suppl):S49-S57.
5. Bays HE, Jones PH, Brown WV, Jacobson TA, National Lipid Association. National Lipid Association annual summary of clinical lipidology 2015. J Clin Lipidol. 2014;8(suppl):S1-S36.
6. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499.
7. Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials. Int J Cardiol. 2016;223:750-757.
8. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186-1194.
9. Colhoun HM, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord. 2014;14:121.
10. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996-3003.
11. Colhoun HM, Ginsberg HN, Robinson JG, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J. 2016;37:2981-2989.
12. Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4:403-410.
13. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168:682-689.